Allurion Technologies Earnings Call Transcripts
Fiscal Year 2025
-
Q3 revenue declined year-over-year due to restructuring, but operating losses narrowed significantly as cost efficiencies took hold. Major FDA milestones were achieved, and a debt-for-equity exchange plus private placement strengthened the balance sheet.
-
Q2 2025 revenue declined year-over-year due to distributor transitions, but direct markets and clinics piloting combination therapy grew. Operating expenses fell 48% from restructuring, and the FDA PMA submission was completed with strong clinical data.
-
The company’s non-invasive weight loss program, combining a swallowable balloon, behavior change, and AI-powered virtual care, has shown strong clinical results and financial discipline. U.S. market entry is expected within a year, with the full program and AI features, targeting significant growth and profitability.
-
Q1 2025 saw revenue of $5.6M and gross margin expansion to 75%, with operating expenses and losses significantly reduced year-over-year. The business is executing a five-pillar plan, advancing FDA approval, and expects steady revenue growth and margin stability through 2025.
-
Obesity remains a vast, underserved market, with Allurion offering a procedureless, AI-supported weight loss solution that delivers strong clinical results and safety. The company has shifted to a B2B2C model, reduced costs, and is targeting FDA approval and a US launch in 2026.
Fiscal Year 2024
-
Q4 2024 revenue was $5.6M, with full year revenue at $32.1M and a 4% increase in procedure volumes. Restructuring reduced OpEx by 39% in Q4, and 2025 revenue is guided at $30M with further margin expansion expected. Combination therapy with GLP-1s is showing strong clinical promise.
-
Q3 revenue fell sharply due to France suspension and recall, but AI product revenue grew over 80% year-over-year. Major restructuring aims to cut operating expenses by 50% in 2025, with a focus on AI, commercial realignment, and FDA approval.
-
Q2 revenue rose 25% sequentially to $11.8M, with record procedure volumes and improved operational efficiency. Guidance was lowered due to France's regulatory suspension and macro headwinds, but profitability is targeted by end of 2025.
-
A differentiated, procedureless gastric balloon paired with an AI-powered digital platform is driving strong patient outcomes and engagement, with significant market opportunity in the underpenetrated obesity space. Financial discipline, a robust clinical pipeline, and U.S. market entry are key near-term catalysts.
-
A procedureless, swallowable balloon paired with a digital program is driving strong weight loss outcomes and commercial growth, with 2024 guidance targeting $60–$65 million in revenue and significant cash burn reduction. NHS reimbursement in the U.K. and digital platform expansion are key growth drivers.